HC Wainwright Reaffirms Buy Rating for Atossa Therapeutics (NASDAQ:ATOS)

HC Wainwright reissued their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a report published on Friday, Benzinga reports. The brokerage currently has a $6.00 price objective on the stock.

Several other equities analysts have also issued reports on the company. StockNews.com raised Atossa Therapeutics from a sell rating to a hold rating in a research report on Tuesday, May 14th. Cantor Fitzgerald reissued an overweight rating on shares of Atossa Therapeutics in a research report on Thursday, June 20th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Atossa Therapeutics from $6.00 to $6.25 and gave the stock a buy rating in a report on Thursday, June 6th.

Atossa Therapeutics Stock Performance

Shares of ATOS stock opened at $1.19 on Friday. The firm has a market cap of $149.65 million, a P/E ratio of -4.96 and a beta of 1.19. The business’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.23. Atossa Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. As a group, equities analysts predict that Atossa Therapeutics will post -0.23 EPS for the current year.

Insider Buying and Selling at Atossa Therapeutics

In related news, Director Jonathan Finn purchased 25,000 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were purchased at an average price of $1.77 per share, with a total value of $44,250.00. Following the acquisition, the director now directly owns 25,000 shares in the company, valued at approximately $44,250. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATOS. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Atossa Therapeutics in the third quarter worth $98,000. Virtu Financial LLC purchased a new position in Atossa Therapeutics in the first quarter worth about $151,000. Vanguard Group Inc. grew its stake in shares of Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares during the period. Cetera Advisors LLC purchased a new stake in shares of Atossa Therapeutics during the 1st quarter valued at about $72,000. Finally, PFG Investments LLC bought a new position in shares of Atossa Therapeutics in the 1st quarter worth approximately $43,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.